A Faegre Drinker litigation team received a favorable ruling for client biotechnology company Regeneron Pharmaceuticals in a False Claims Act (FCA) kickback theory case. U.S. District Chief Judge of the District of Massachusetts F. Dennis Saylor IV ruled that the federal government must prove that alleged kickbacks by Regeneron related to its drug Eylea had a direct connection to false claims. The noteworthy ruling addresses an issue that has prompted a significant circuit split.
Judge Saylor said the government must show at trial that any alleged kickbacks by Regeneron were the "but-for" cause of subsequent false claims, a standard regarding a contested issue of FCA law previously adopted by the Sixth and Eighth circuits.
See Law360’s coverage of the case and verdict for more details.
